Loading
A phase 1/2 trial in triple-negative breast cancer, run by Nova Scotia Health Authority, not yet recruiting.
Efficacy of Interleukin-2 in Triple Negative Breast Cancer is a phase 1/2, interventional study registered as NCT05821686 by Nova Scotia Health Authority, with a registry enrolment figure of 10 participants, started 2026-01-02 and due to reach its primary completion in 2028-04. Interventions recorded: Human Interleukin-2 (IL-2) (Proleukin). Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Women with biopsy proven TNBC who are not scheduled to receive neoadjuvant chemotherapy". No results are recorded here; the registry entry is the source.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.